As Biotechnology businesses, aTyr Pharma Inc. (NASDAQ:LIFE) and Coherus BioSciences Inc. (NASDAQ:CHRS), are affected by compare. This especially applies to their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|aTyr Pharma Inc.||6||0.00||N/A||-13.68||0.00|
|Coherus BioSciences Inc.||17||10.71||N/A||-2.66||0.00|
Table 1 shows the gross revenue, earnings per share and valuation for aTyr Pharma Inc. and Coherus BioSciences Inc.
Table 2 shows us aTyr Pharma Inc. and Coherus BioSciences Inc.’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|aTyr Pharma Inc.||0.00%||-81.3%||-52%|
|Coherus BioSciences Inc.||0.00%||0%||-120.3%|
Volatility and Risk
A 2.3 beta indicates that aTyr Pharma Inc. is 130.00% more volatile compared to Standard and Poor’s 500. In other hand, Coherus BioSciences Inc. has beta of 3.05 which is 205.00% more volatile than Standard and Poor’s 500.
The Current Ratio and Quick Ratio of aTyr Pharma Inc. are 4 and 4 respectively. Its competitor Coherus BioSciences Inc.’s Current Ratio is 3.8 and its Quick Ratio is 3.8. aTyr Pharma Inc. can pay off short and long-term obligations better than Coherus BioSciences Inc.
The Ratings and Recommendations for aTyr Pharma Inc. and Coherus BioSciences Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|aTyr Pharma Inc.||0||0||0||0.00|
|Coherus BioSciences Inc.||0||0||5||3.00|
Competitively the consensus price target of Coherus BioSciences Inc. is $30.2, which is potential 63.16% upside.
Insider & Institutional Ownership
Roughly 35.3% of aTyr Pharma Inc. shares are owned by institutional investors while 97.45% of Coherus BioSciences Inc. are owned by institutional investors. Insiders owned roughly 0.1% of aTyr Pharma Inc.’s shares. Competitively, Coherus BioSciences Inc. has 0.3% of it’s share owned by insiders.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|aTyr Pharma Inc.||-4.88%||-35.74%||-59.99%||-49.87%||-69.24%||-49.42%|
|Coherus BioSciences Inc.||-5.51%||-25.31%||5.45%||28.69%||-6.56%||85.86%|
For the past year aTyr Pharma Inc. had bearish trend while Coherus BioSciences Inc. had bullish trend.
Coherus BioSciences Inc. beats aTyr Pharma Inc. on 6 of the 8 factors.
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy (FSHD), early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. Its discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines. The company was founded in 2005 and is headquartered in San Diego, California.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonÂ–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, BehÃ§et’s Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.